Tags

Type your tag names separated by a space and hit enter

Medications Approved for Preventing Migraine Headaches.
Am J Med. 2020 06; 133(6):664-667.AJ

Abstract

Migraine is the third-most prevalent disease in the world and affects approximately 39 million individuals in the United States alone. Migraine occurs in nearly 1 in 7 individuals between 15 and 49 years of age and is 3 times more frequent in women than in men. The Food and Drug Administration (FDA) recently approved 3 new humanized monoclonal antibodies that target calcitonin gene-related peptide (CGRP): erenumab, fremanezumab, and galcanezumab. The agents either bind to the CGRP receptor (erenumab) or bind to the CGRP ligand (fremanezumab and galcanezumab) and block its binding to the receptor. All 3 products are indicated for preventative treatment of episodic or chronic migraine in adults. The available studies to date document that these agents reduce migraine attacks. The CGRP monoclonal antibodies offer patients new options once they have exhausted other treatments.

Authors+Show Affiliations

University of Kentucky College of Pharmacy, Lexington.University of Kentucky College of Pharmacy, Lexington. Electronic address: melody.ryan@uky.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32145209

Citation

Spindler, Brittany L., and Melody Ryan. "Medications Approved for Preventing Migraine Headaches." The American Journal of Medicine, vol. 133, no. 6, 2020, pp. 664-667.
Spindler BL, Ryan M. Medications Approved for Preventing Migraine Headaches. Am J Med. 2020;133(6):664-667.
Spindler, B. L., & Ryan, M. (2020). Medications Approved for Preventing Migraine Headaches. The American Journal of Medicine, 133(6), 664-667. https://doi.org/10.1016/j.amjmed.2020.01.031
Spindler BL, Ryan M. Medications Approved for Preventing Migraine Headaches. Am J Med. 2020;133(6):664-667. PubMed PMID: 32145209.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medications Approved for Preventing Migraine Headaches. AU - Spindler,Brittany L, AU - Ryan,Melody, Y1 - 2020/03/05/ PY - 2019/12/09/received PY - 2020/01/20/revised PY - 2020/01/21/accepted PY - 2020/3/8/pubmed PY - 2020/8/18/medline PY - 2020/3/8/entrez KW - Calcitonin gene-related peptide (CGRP) KW - Headache KW - Migraine SP - 664 EP - 667 JF - The American journal of medicine JO - Am J Med VL - 133 IS - 6 N2 - Migraine is the third-most prevalent disease in the world and affects approximately 39 million individuals in the United States alone. Migraine occurs in nearly 1 in 7 individuals between 15 and 49 years of age and is 3 times more frequent in women than in men. The Food and Drug Administration (FDA) recently approved 3 new humanized monoclonal antibodies that target calcitonin gene-related peptide (CGRP): erenumab, fremanezumab, and galcanezumab. The agents either bind to the CGRP receptor (erenumab) or bind to the CGRP ligand (fremanezumab and galcanezumab) and block its binding to the receptor. All 3 products are indicated for preventative treatment of episodic or chronic migraine in adults. The available studies to date document that these agents reduce migraine attacks. The CGRP monoclonal antibodies offer patients new options once they have exhausted other treatments. SN - 1555-7162 UR - https://www.unboundmedicine.com/medline/citation/32145209/Medications_Approved_for_Preventing_Migraine_Headaches_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9343(20)30143-1 DB - PRIME DP - Unbound Medicine ER -